Questcor Acthar Gel Has Mid-’07 Action Date For Infantile Spasms, But Ovation To Seek Same Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Ovation plans to submit vigabatrin for the same indication in the coming weeks.
You may also be interested in...
Questcor Evaluating Development Strategies Following Acthar “Not Approvable” Letter
Competing firm Ovation tells “The Pink Sheet” DAILY it plans to submit its anticonvulsant vigabatrin for infantile spasms later this year.
Questcor Evaluating Development Strategies Following Acthar “Not Approvable” Letter
Competing firm Ovation tells “The Pink Sheet” DAILY it plans to submit its anticonvulsant vigabatrin for infantile spasms later this year.
Ovation Acquires Lundbeck's Antipsychotic Buronil
Gaining FDA approval of melperone and two other recently acquired products – the anti-epileptics Sabril (vigabatrin) and Frisium (clobazam) – is a top priority for Ovation. The company has built a portfolio of 11 "under-performing" CNS products in less than two years.